Lepu Medical
Lepu Medical Technology (Beijing) Co., Ltd., established in 1999, is a prominent Chinese company that develops, manufactures, and markets advanced medical devices and equipment. The company specializes in various areas, including cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics, and general surgery. Its product offerings include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, electrophysiology catheters, pacemakers, in vitro diagnostic equipment, biomarkers, DSA systems, and surgical staplers. Lepu Medical has established itself as a global leader in these fields, demonstrating a commitment to innovation and quality in healthcare solutions.
7 past transactions
Shenda Endoscope
Series C in 2023
Shenda Endoscope develops and manufactures medical rigid endoscopes that use French optical materials and optical fiber to ensure the performance and quality of endoscopes.
Guizhou Yizhiying Technology
Series A in 2023
Guizhou Yizhiying Technology is an enterprise specializing in the field of artificial intelligence medical treatment. It intelligently analyzes medical image big data as it relies on self-developed core technologies of deep learning and medical image analysis.
Inspirna
Series D in 2022
Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.
Lepu Bio
Series A in 2019
Lepu Biotechnology Co., Ltd. is a Chinese biotech company specializing in tumor immunotherapy. Founded in 2018, it has developed an industrial platform dedicated to target discovery, drug preparation, development, and manufacturing. The company focuses on creating drug candidates that include programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies, an oncolytic virus, and various antibody-drug conjugates (ADCs). Lepu Bio's core products are currently in clinical stages I to III, demonstrating its commitment to advancing cancer treatment through innovative biopharmaceutical solutions.
24tidy
Series C in 2018
24tidy is a family service platform based in China, specializing in laundry and cleaning services. The company offers users the ability to schedule pickups and drop-offs for laundry and dry cleaning items at their convenience across more than ten cities. In addition to its core laundry services, 24tidy also provides supplementary family services, including weekly flower delivery and potted plant rental. By leveraging advanced internet technology, the platform aims to enhance users' quality of life by promoting a cleaner and more organized living environment. Its commitment to fast, convenient, and high-quality services ensures that customers receive exceptional care for their clothing, shoes, bags, and home textiles, helping them maintain a fresh and tidy lifestyle.
Inspirna
Series C in 2018
Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.
Youjiali
Series A in 2015
Youjiali is an artificial intelligence ECG-assisted analysis technology and mobile ECG medical equipment. They provide complete health and medical service ecosystem.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.